Back to News
Market Impact: 0.2
Astellas Pharma Signs DAX-044 Immuno-Oncology Deal Worth Up To $1.34 Bln
Source: Nasdaq
Healthcare & BiotechM&A & Restructuring
Astellas Pharma and Australia's Audax Biosciences announced an exclusive option and license agreement for DAX-044, Audax's lead immuno-oncology AVIKINE candidate. The article is truncated before the potential deal value and provides no further financial terms or development details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Nvidia's $12.9 billion Hugging Face deal draws DOJ scrutiny
- Chipotle Mexican Grill is about to report earnings. Here's what to expect
- Peltz’s Trian Offers $1.4 Billion for Wendy’s, WSJ Reports
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%